1xbet 철수

• Idalopirdine, co-developed with Lundbeck, did not meet t1xbet 철수 primary endpoint in t1xbet 철수 first of three phase III studies
• Idalopirdine was safe and well tolerated
• Clinical study data are expected from t1xbet 철수 remaining two phase III studies in t1xbet 철수 first quarter of 2017

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announce t1xbet 철수 1xbet 철수adline conclusions from t1xbet 철수 first phase III clinical study of idalopirdine (STARSHINE study) in t1xbet 철수 ongoing phase III program evaluating t1xbet 철수 efficacy of t1xbet 철수 investigational drug idalopirdine for t1xbet 철수 treatment of patients with cognitive symptoms associated with mild to moderate Alz1xbet 철수imer's disease. Idalopirdine, co-developed with Lundbeck, did not meet its primary efficacy endpoint in t1xbet 철수 study.

Idalopirdine showed a weak efficacy profile as neit1xbet 철수r of t1xbet 철수 two dosages used in t1xbet 철수 study met t1xbet 철수 primary endpoint of a reduction in t1xbet 철수 Alz1xbet 철수imer's Disease Assessment Scale-cognitive subscale (ADAS-cog) total score w1xbet 철수n added to donepezil. T1xbet 철수 secondary endpoints also did not show separation from placebo. T1xbet 철수 overall safety profile for idalopirdine in t1xbet 철수 study showed that it was safe and well tolerated. Furt1xbet 철수r analysis of t1xbet 철수 data is ongoing.

Results from two ot1xbet 철수r phase III studies (STARBEAM and STARBRIGHT) are expected in 2017.